Targeting cannabinoid agonists for inflammatory and neuropathic pain
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
The cannabinoid receptors CB(1) and CB(2) are class A G-protein-coupled receptors. It is well known that cannabinoid receptor agonists produce relief of pain in a variety of animal models by interacting with cannabinoid receptors. CB(1) receptors are located centrally and peripherally, whereas CB(2) receptors are expressed primarily on immune cells and tissues. A large body of preclinical data supports the hypothesis that either CB(2)-selective agonists or CB(1) agonists acting at peripheral sites, or with limited CNS exposure, will inhibit pain and neuroinflammation without side effects within the CNS. There has been a growing interest in developing cannabinoid agonists. Many new cannabinoid ligands have been synthesized and studied covering a wide variety of novel structural scaffolds. This review focuses on the present development of cannabinoid agonists with an emphasis on selective CB(2) agonists and peripherally restricted CB(1) or CB(1)/CB(2) dual agonists for treatment of inflammatory and neuropathic pain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092 · cited 2×
“Human CB1 and CB2 receptors share 44% of overall identity and have a 68% homology of their amino acid sequence within the transmemebrane domains [2].”
BackgroundStructure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913 · cited 1×
“Endogenous ligands for cannabinoid receptors include anadamide, 2-arachidonylglycerol and other fatty acid derivatives [6-8].”
BackgroundInternational Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
Identification and Functional Characterization of Brainstem Cannabinoid CB2Receptors
Van Sickle, M. D., Duncan, M., Kingsley, P. J., Mouihate, A., Urbani, P., Mackie, K., Stella, N., Makriyannis, A., Piomelli, D., Davison, J. S., et al. (2005) · Science · doi:10.1126/science.1115740 · Cited by 1,470
Zhang, J., Hoffert, C., Vu, H. K., Groblewski, T., Ahmad, S., & O'Donnell, D. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02704.x · Cited by 419
CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms
Beltramo, M., Bernardini, N., Bertorelli, R., Campanella, M., Nicolussi, E., Fredduzzi, S., & Reggiani, A. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04684.x · Cited by 290 · cited 3×
“Futhermore, the in vivo analgesic effects of AM1241 were blocked by a CB2 antagonist, but not by a CB1 antagonist and the analgesic effects were not observed in CB2 knockout mice [16,18-23].”
BackgroundValenzano, K. J., Tafesse, L., Lee, G., Harrison, J. E., Boulet, J. M., Gottshall, S. L., Mark, L., Pearson, M. S., Miller, W., Shan, S., et al. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.12.008 · Cited by 288 · cited 2×
“It has ∼ 1200-fold and 80-fold selectivity, respectively, for recombinant human and native rat CB2 versus CB1 receptors by binding affinity [24].”
BackgroundManzanares, J., Julian, M., & Carrascosa, A. (2006) · Current Neuropharmacology · doi:10.2174/157015906778019527 · Cited by 287 · cited 1×
“Many reports have demonstrated that cannabinoid compounds show good activity in animal models of inflammatory and neuropathic pain (readers are referred to the reviews in [11-13]).”
BackgroundPeripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons
Wotherspoon, G., Fox, A., McIntyre, P., Colley, S., Bevan, S., & Winter, J. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.06.009 · Cited by 251 · cited 1×
“Drugs (2007) 16(7) be induced in neural cells by peripheral nerve injury in rats [34,35].”
Background
Cited by
Zhao, C., Rakesh, K. P., Ravidar, L., Fang, W.-Y., & Qin, H.-L. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.11.017 · Cited by 651
Brown, A. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707481 · Cited by 409
Huggins, J. P., Smart, T. S., Langman, S., Taylor, L., & Young, T. (2012) · Pain · doi:10.1016/j.pain.2012.04.020 · Cited by 375
“A large body of evidence in behavioural rodent models suggests activation of these receptors may ameliorate chronic pain [13,41].”
BackgroundNeugebauer, V., Galhardo, V., Maione, S., & Mackey, S. C. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.12.014 · Cited by 353
Benzimidazole: An emerging scaffold for analgesic and anti-inflammatory agents
Gaba, M., Singh, S., & Mohan, C. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.01.030 · Cited by 344
Metadata
- Authors
- Cheng, Y., & Hitchcock, S. A.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2007-06-26
- Volume
- 16
- Issue
- 7
- Pages
- 951-965
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2130261677
- Cited by
- 102
- References
- 13
- FWCI
- 6.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting cannabinoid agonists for inflammatory and neuropathic pain. https://app.cochat.ai/papers/10.1517/13543784.16.7.951
- The paper
- Cheng, Y., & Hitchcock, S. A. (2007). Targeting cannabinoid agonists for inflammatory and neuropathic pain. Expert Opinion on Investigational Drugs. https://doi.org/10.1517/13543784.16.7.951
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.